Citation Report
List of articles citing

Tadalafil for the treatment of pulmonary arterial hypertensio

DOI: 10.1586/ers.11.38
Expert Review of Respiratory Medicine, 2011, 5, 315-28.

Source: https://exaly.com/paper-pdf/50393782/citation-report.pdf
Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
7	Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension. *Vascular Pharmacology*, **2013**, 58, 211-8	5.9	16
6	Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. *Therapeutic Advances in Respiratory Disease*, **2013**, 7, 39-49	4.9	13
5	Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition. *Journal of Translational Medicine*, **2014**, 12, 314	8.5	14
4	Mixed connective tissue disease. *Best Practice and Research in Clinical Rheumatology*, **2016**, 30, 95-111	5.3	60
3	Update on novel targets and potential treatment avenues in pulmonary hypertension. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2016**, 311, L811-L831	5.8	14
2	The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats. *Canadian Journal of Physiology and Pharmacology*, **2018**, 96, 1308-1317	2.4	20
1	Diketopiperazine-Based, Flexible Tadalafil Analogues: Synthesis, Crystal Structures and Biological Activity Profile. *Molecules*, **2021**, 26,	4.8	4